What per-batch documentation to ask a compounding pharmacy for

What should you actually be asking about?

A preparation and a shipment — not the pharmacy in general.

Most diligence conversations stay at the level of the business: are you accredited, are you licensed, how long have you been operating. Those are worth asking and they are answered elsewhere. But the questions that produce a checkable answer attach to a specific thing arriving at a specific address: which lot, dated to when, labelled how, made against what record.

The reason is that general questions have general answers and specific ones do not. "Do you follow good practice" invites a sentence. "What will the container label read for lot number and beyond-use date, and can you send me a specimen label before I order" invites either a document or a refusal, and both are informative.

What is a lot number for?

It is the handle that makes every other record retrievable — which is why the rules that require records require this field by name.

A lot identifies a discrete batch. Without it, a quality question about the vial in your fridge cannot be connected to the compounding that produced it, to the other units from the same batch, or to any testing performed on it. With it, all of those become one query.

Several states make that explicit. Illinois requires the lot number in the office-use record it mandates. Georgia requires a veterinarian receiving office-use stock to chart the lot number. Texas requires an office-use audit trail that can be queried by lot number among other fields. New Jersey requires preparations compounded in anticipation of a prescription to carry unique batch numbers, with the lots and expiration dates of the drugs, containers and diluents themselves documented.

What is a beyond-use date, and what is it not?

It is the point after which a compounded preparation may not be used — and it is not an expiration date, because the two rest on different evidence.

Ohio's rule defines it directly: a beyond-use date "means either the date or time and date after which a compounded drug preparation must not be used or administration must not begin."

An expiration date is a different object. Under federal current good manufacturing practice, a drug product "shall bear an expiration date determined by appropriate stability testing." A preparation from a state-licensed 503A pharmacy carries a beyond-use date assigned under the USP chapter its state has adopted, a conservative default keyed to dosage form and compounding conditions. A product from a facility registered with FDA under section 503B is made under CGMP, where dating is tied to stability testing on that product.

That is a difference in the kind of evidence behind the date. It is not a claim that either one lasts longer, and no honest page can turn it into one. The term is defined further at beyond-use date.

Why does the beyond-use date depend on which version of a chapter they follow?

Because adoption is staggered by state and version-dated, and the newer dating is something a pharmacy has to earn.

Ohio is the clearest published case. Its Board delayed enforcement of its USP chapter rule until 28 February 2027, and its guidance states the consequence in terms: "Only licensees that have fully adopted the newest versions may utilize the new beyond-use dates in USP 797 & USP 795." The same document is blunter still: licensees "are prohibited from utilizing beyond-use dates from the newest versions of USP 797/795 unless they can demonstrate full compliance with those new versions."

Two pharmacies answering to different boards can therefore both be fully compliant while working to different editions of the same chapter, with different dating. That gives you a question with a right answer: which version are you dating to, and — if your state is running a transition — can you demonstrate full compliance with the version whose dating you are using?

What is in the compounding record, and who has to keep it?

The pharmacy does, for a period its state sets, and the required contents are more specific than most buyers expect.

Two things are worth noticing about the Illinois list. It identifies the ordering practitioner by name and address, not by DEA number — a pattern that holds in the Texas audit trail too, and one taken further at do I need a DEA number to order compounded medications. And it ties the lot number and the beyond-use date together in the same record, which is why asking for one and not the other leaves the record half-read.

Can you require any of this?

No — and being clear-eyed about that makes the conversation more productive, not less.

Every obligation above runs to the pharmacy and to its regulator. None of them creates an entitlement for a prescriber to receive a copy. A supplier who declines to hand over an underlying compounding record is not breaking a rule, and treating a refusal as misconduct will get you a worse answer than treating it as a commercial negotiation.

What the rules do give you is leverage of a different kind: you know the record exists, you know roughly what is in it, and you know how long it has to be available. That converts a vague ask into a precise one, and precise asks are harder to deflect with a brochure.

What about a certificate of analysis?

Many pharmacies will provide one. We could not verify any rule requiring them to, and we are not going to imply otherwise.

A certificate of analysis reports testing on a specific lot. It is the natural artefact of sterile compounding requirements and it is common industry practice, which is why the request is reasonable and usually met. But we found no provision, in any state we read, compelling disclosure of one to a prescriber.

Frame the question accordingly: will you provide a certificate of analysis for the lot I receive, and what does it report? The second half matters as much as the first, because "we provide a COA" describes a document's existence rather than its contents, and what is tested — identity, potency, sterility, endotoxin, impurities — is the part that bears on your decision.

What should the container label itself show?

Enough to connect the vial in front of you to the record behind it — and in several states the rule says so.

Illinois requires the beyond-use date on every office-use container label, and requires office-use containers to carry a legend marking them as office use and not for resale. Louisiana's labelling set includes the beyond-use date, and requires preparations compounded in anticipation of prescriptions to carry a reference to the formula, an assigned lot number and an estimated beyond-use date. Georgia requires the receiving veterinarian to chart the lot number and beyond-use date for office-use stock.

Ask for a specimen label before the first order rather than after it. A label is the cheapest document in this entire exercise to obtain, it is the one you will actually look at every time you draw a dose, and a supplier that cannot produce a sample of its own label in advance has told you something about its documentation generally.

Where does this sit in the rest of the check?

This is the part of diligence that depends on the supplier's cooperation. The half that does not — federal registration, the published enforcement record, the state credential — is set out at how to vet a compounding pharmacy, with the instruments at how to read FDA’s registered-outsourcing-facilities list and how to verify a compounding pharmacy’s state licence.

What the quality standards behind these records actually are, and what an accreditation attests about them, is at PCAB accreditation. Which pathway your preparation is being supplied under is at 503A vs 503B, and the date on the label is defined at beyond-use date.

To have these questions asked of a supplier once, on your behalf, rather than per order, you can apply for an account.